Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

BACKGROUND Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. METHODS We randomly assigned 1583 patients with symptomatic knee osteoarthritis to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. RESULTS The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. CONCLUSIONS Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain. (ClinicalTrials.gov number, NCT00032890.).

[1]  N. Bellamy.  Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. , 1989, Seminars in arthritis and rheumatism.

[2]  V. Welch,et al.  Glucosamine therapy for treating osteoarthritis. , 2005, The Cochrane database of systematic reviews.

[3]  M. Dougados,et al.  OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. , 2004, Osteoarthritis and cartilage.

[4]  C. Helmick,et al.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.

[5]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[6]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[7]  S. Litschig,et al.  Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib , 2005, Current medical research and opinion.

[8]  J. Deeks,et al.  Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials , 2002, BMJ : British Medical Journal.

[9]  T. Schnitzer,et al.  Guidelines for the medical management of osteoarthritis. II: Osteoarthritis of the knee , 1995 .

[10]  D. Felson,et al.  Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. , 2000, JAMA.

[11]  J. Kellgren,et al.  Radiological Assessment of Osteo-Arthrosis , 1957, Annals of the rheumatic diseases.

[12]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[13]  R. Moskowitz,et al.  Design and conduct of clinical trials in osteoarthritis: preliminary recommendations from a task force of the Osteoarthritis Research Society. , 1997, The Journal of rheumatology.

[14]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[15]  Zhongmin Liang,et al.  Analysis of Glucosamine and Chondroitin Sulfate Content in Marketed Products and the Caco-2 Permeability of Chondroitin Sulfate Raw Materials , 2000 .

[16]  K. Pavelka,et al.  Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. , 2002, Archives of internal medicine.

[17]  Eric Lejeune,et al.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial , 2001, The Lancet.

[18]  T. Schnitzer,et al.  Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. , 1995, Arthritis and rheumatism.

[19]  B. Mazières,et al.  [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. , 1992, Revue du rhumatisme et des maladies osteo-articulaires.

[20]  I. Russell,et al.  Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. , 1993, Arthritis and rheumatism.

[21]  R. Altman.  Design and conduct of clinical trials in osteoarthritis. , 1990, Scandinavian journal of rheumatology. Supplement.

[22]  R. Moskowitz,et al.  Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. , 1998, The Journal of rheumatology.

[23]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[24]  T. McAlindon,et al.  Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. , 2004, The American journal of medicine.

[25]  T. Schnitzer,et al.  Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. , 1995, Arthritis and rheumatism.

[26]  T. Schnitzer,et al.  Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. , 2005, The Journal of rheumatology.

[27]  C Michael Stein,et al.  Cardiovascular toxicity of valdecoxib. , 2004, The New England journal of medicine.

[28]  J. Bolognese,et al.  Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. , 2000, Arthritis and rheumatism.

[29]  J. Singer,et al.  Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. , 2004, Arthritis and rheumatism.

[30]  R. Chang,et al.  The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[31]  J. Houpt,et al.  Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. , 1999, The Journal of rheumatology.

[32]  T. Conrozier.  [Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6)]. , 1998, Presse medicale.

[33]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[34]  F. Jamali,et al.  Active ingredient consistency of commercially available glucosamine sulfate products. , 2002, The Journal of rheumatology.

[35]  K. Brandt,et al.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. , 1991, The New England journal of medicine.